Donate Now
  • What We're Working On
Individualizing rheumatoid arthritis therapy
pexels-nataliya-vaitkevich-7615415-scaled
Scientific Study Title:
Personalizing the choice of therapy in rheumatoid arthritis.
Start Date:
  • 2022
End Date:
  • 2026
Research Category
Tags

Why do this research?

Rheumatoid Arthritis is a chronic autoimmune disease that can affect adults of any age. People living with rheumatoid arthritis have difficulty with every day activities, due to joint pain, swelling and fatigue. Medications, called ‘disease-modifying anti-rheumatic drugs’ (DMARDs) are used to control joint inflammation. Today, there are many medications available, so determining the ‘best’ treatment option for a patient should be based on the most current data and patient preferences.

What will be done?

In this study we will develop a personalized decision tool to help patients choose the best treatment option for them. Data will be analyzed from all trials conducted to date and from over 10,000 patients in Canada. A risk calculator will be developed to assess treatment benefits and risk, for each patient. Guidelines will be developed along with this tool and implemented into clinical practice. The goal is to develop a tool to help patients select the best treatment for them.

It is intended that the tool will be utilized in the rheumatology office by the patient and physician together.

The Research Team

Principal Investigator

  • Glen Hazlewood, MD, PhD, FRCPC, Research Scientist, Rheumatology, Arthritis Research Canada (University of Calgary)
  • George Wells – MSc, PhD, Professor, School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa

Co-investigators

  • Nick Bansback, MSc, PhD, Research Scientist, Health
  • Economics, Arthritis Research Canada (University of British Columbia)
  • Claire Barber, MD, PhD, FRCPC, Research Scientist, Rheumatology, Arthritis Research Canada (University of Calgary)
  • Cheryl Barnabe, MD, MSc, FRCPC, Senior Scientist, Rheumatology, Arthritis Research Canada (University of Calgary)
  • Claire Bombardier, Vivian Bykerk, Alexandra Charlton, Denis Choquette, Rob Deardon, Jesse Elliott, Mohammed Mujaab Kamso, Shannon Kelly, Laurie Proulx, Dawn Richards, Orit Schieir, Jocelyn Thomas

How Can People Get Involved?

The research team includes several rheumatologists, researchers and patient partners from across Canada.

Media and Infographics

Related Research

What We're Working On Right Now

Exploring a New Immune Cell Therapy for People with Autoimmune Diseases

Systemic sclerosis and systemic lupus erythematosus are serious autoimmune diseases that can cause damage to many organs including the skin, lungs and kidneys. In this project, we will study a new type of treatment that may better control these diseases by targeting the immune cells that cause them. If successful, it could reduce inflammation, slow or stop disease progression, and may even help reset the immune system, so that some patients no longer need long-term immune-suppressing medications.
Read More

Understanding how scleroderma affects people over time

People living with scleroderma experience challenges such as pain, disability, and mental health concerns, but we still don’t know much about how these problems change over time or why some people do better than others. For this research project, our goal is to improve our understanding of how scleroderma affects people’s daily lives and identify factors that may predict changes in their health.
Read More

How can we help Canadians age at home to improve health outcomes and support a sustainable healthcare system?

As Canada’s population ages, home care is important for helping older adults remain safely within their homes. Our research team is linking data from the Canadian Longitudinal Study on Aging with health records in British Columbia, Ontario, and New Brunswick, to track patterns of paid and unpaid home care use over time.
Read More